Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
24 hedge funds and large institutions have $1.77M invested in Albireo Pharma Inc in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
17% less funds holding
Funds holding: 29 → 24 (-5)
23% less capital invested
Capital invested by funds: $2.3M → $1.77M (-$527K)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$64.1K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$23K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$16.4K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$318K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$118K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$75.8K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$42.2K |
| 5 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$27K |
ALBO Hedge Fund Activity: Q2 2016 in Review
24 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2016, worth a combined $1.77M — down 23% from $2.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ALBO and 1 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $64.1K. The largest seller was Fidelity Investments, exiting entirely with an estimated $318K sold.
- 24 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2016, down from 29 in Q1 2016.
- Funds reported $1.77M of Albireo Pharma Inc stock for Q2 2016, down 23% quarter-over-quarter.
- 1 fund opened new Albireo Pharma Inc positions in Q2 2016 and 6 closed out, a net change of -5 holders.
- The largest Albireo Pharma Inc buyer in Q2 2016 was Renaissance Technologies, an estimated $64.1K added.
- The largest Albireo Pharma Inc seller in Q2 2016 was Fidelity Investments, an estimated $318K sold.
Based on aggregated 13F filings for Q2 2016.